Lithium Australia announces maiden Resource estimate in Germany

|

Published 07-DEC-2017 08:02 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

As the global lithium arms race continues, Australian resources companies are keen to stay ahead of developments. As a commodity, lithium is on-track to carve out its own distinct market niche fuelled by lithium-ion batteries; therefore, the chase for ample high-grade lithium resources has begun in earnest.

Keen on synchronising its own development with that of the broader lithium market is Lithium Australia (ASX:LIT).

Just this week, LIT has announced a maiden lithium Mineral Resource estimate for its recently-acquired Sadisdorf project in Saxony, Germany.

Sadisdorf lithium project

Source: Lithium Australia

LIT’s maiden estimate was conducted by CSA Global, who’ve estimated an Inferred Mineral Resource of 25 million tonnes grading 0.45% Li2O, based on re-analysis and re-interpretation of historical drilling and underground sampling at Sadisdorf.

The formal Resource statement substantially enhances LIT’s chances of progressing the Sadisdorf tin-tungsten mine to a polymetallic deposit with value contributions from lithium, tin and tungsten, as well as from a range of potassium by-products.

With the implementation of LIT’s patented SiLeach process, LIT is able to source additional quantities of potassium sulphate fertiliser and sodium silicate from the same ore which is expected to supplement LIT’s revenues and smooth out the path to economic viability at Sadisdorf.

LIT intends to provide a full-service solution in lithium by possessing its own lithium resources and patenting a method of extracting high-grade lithium from host rocks, thereby widening the scope from where lithium can be sourced. Longer term, LIT plans to integrate itself into modern lithium mining and processing, courtesy of its list of JV deals, its own Resources and patented SiLeach technology. The Sadisdorf Project in Saxony is logistically well-placed to supply the European battery and electric vehicle market which is growing strongly.

However LIT does remain a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.

LIT Managing Director Adrian Griffin said, “We are in the backyard of the most rapidly expanding consumption of lithium outside China, with most European vehicle manufacturers announcing their plans to go electric. The synergies are obvious, and at Lithium Australia we are well placed to take advantage of that expanding market.

”Our previous testing demonstrates that SiLeach® can unlock the potential of Sadisdorf as a true polymetallic operation, recovering lithium from the residues of conventional tin concentration processes. The size of the Sadisdorf resource is already significant, with the potential to feed a 25,000 tonnes per annum lithium carbonate plant for 10 years. Further exploration is likely to expand the resource significantly. It is noteworthy that Sadisdorf has higher grades than the nearby Cinovec deposit (Czech Republic) and is not far from the Zinnwald deposit of Deutsche Lithium.”

tags

LITHIUM


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X